MDT Q3 FY26: Revenue Up 8.7%, EPS Mixed

Published: February 17, 2026

Medtronic plc

Direct News

Revenue growth: Q3 FY26 reported year-over-year increase of 8.7%.
Nine months ended Jan 23, 2026 total net sales: $26,557 million.
Business mix (9 months): Cardiovascular 38.3%, Neuroscience 28.4%, Medical Surgical 27.6%, Diabetes 10.4%.
Geographic split (9 months): U.S. ~49.8%, International ex-Ireland ~49.8%, Ireland 0.4%.
EPS: Company reported mixed GAAP and non-GAAP EPS results (no single EPS figure disclosed here); non-GAAP excludes items such as intangible amortization and restructuring.
MiniMed separation: restructuring charges of $16 million recorded in Q3 FY26 tied to separation program.
Capital allocation: $5.0 billion share repurchase authorization in place.
Balance sheet: total debt obligations noted at $28,691 million; interest expense was $913 million in FY2025.
Legal exposures: thousands of product-liability plaintiffs across multiple courts related to HVAD matters; no probable loss recorded.
Regulatory and tax matters: ongoing SEC/DOJ inquiries, IRS audits and material unrecognized tax benefits ($2.0 billion net).

Historical Context

This Q3 FY26 report follows a string of strategic and governance moves in 2025 and early 2026. In late 2025 Medtronic announced the MiniMed separation program and recorded related restructuring actions; a senior executive retirement with equity acceleration was disclosed Nov 3, 2025. At the 2025 AGM (Oct 21) twelve directors were re-elected and changes to shareholder rights and voting structure were approved. In Feb 2026 Medtronic disclosed an option to acquire CathWorks to bolster coronary diagnostics. These prior events frame management’s emphasis on portfolio optimization, capital returns and targeted M&A while the company addresses regulatory, legal and tax exposures.

Quarter snapshot and EPS interpretation

Medtronic reported solid top-line momentum in Q3 FY26 with an 8.7% year-over-year revenue increase. Management continues to present both GAAP and non-GAAP earnings measures; the company’s non-GAAP results exclude items that materially affect comparability, including significant intangible amortization and restructuring charges tied to strategic actions such as the MiniMed separation. Because GAAP and non-GAAP EPS diverged, investors should focus on both measures: GAAP reflects the full reported cost of past acquisitions and current restructuring, while non-GAAP is positioned by management to highlight underlying operational performance.

What’s driving revenue — segments and geography

The nine-month results through Jan 23, 2026 show a diversified mix: Cardiovascular is the largest contributor at 38.3% of net sales, followed by Neuroscience (28.4%) and Medical Surgical (27.6%), with Diabetes at 10.4%. Cardiovascular products—including cardiac rhythm and heart-failure therapies, structural heart and coronary/peripheral vascular offerings—remain the primary revenue engine. Geographic exposure is balanced between the U.S. and international markets (each about 49.8% of nine-month sales), limiting concentration risk but maintaining sensitivity to currency moves; company disclosures note material derivative impacts from a strengthening U.S. dollar.

Capital allocation, innovation and strategic moves

Medtronic’s capital strategy combines share repurchases (a $5.0 billion authorization) with debt management; the company carried roughly $28.7 billion of obligations as of FY2025. Strategic R&D funding arrangements (including Blackstone-funded programs) and recent M&A activity provide optionality: Medtronic has an option to acquire CathWorks announced in Feb 2026 (consideration up to $585 million plus contingent payments) to strengthen coronary diagnostics. Management is also pursuing the MiniMed separation to sharpen focus on Diabetes while reallocating corporate resources.

Risk profile investors should weigh

Material legal and regulatory risks persist. The company faces thousands of product-liability plaintiffs in multiple jurisdictions related to prior product exits; Medtronic’s filings state no probable loss has been recorded for those matters. Antitrust, anti-corruption inquiries and ongoing tax audits (with $2.0 billion of net unrecognized tax benefits disclosed) add further potential volatility. Operationally, restructuring charges tied to separations and EU MDR compliance costs were noted; these items can materially affect GAAP profitability in the near term.

Investor FAQ

The most effective approach is to maintain a factual perspective. Keep a close watch on further developments at Medtronic plc as they unfold. Use primary source data to validate your investment thesis rather than relying on delayed secondary reports.

You can set up an automated tracker on Portrak. Our system monitors official SEC filings in real-time, delivering the most critical insights to your phone or inbox seconds after publication—frequently before the information reaches major financial news platforms.

We believe quality intelligence should be accessible. Our business model is supported by professional investors with large, complex portfolios who utilize Portrak Pro. These users pay to automate the monitoring of extensive watchlists, saving hundreds of hours in research time, which allows us to keep the standard service free for individual investors tracking their core positions.

Setting up your automated intelligence pipeline is a simple 3-step process:

Create Your Free Account

Select Your Focus

Use the search bar to find companies like Medtronic plc. Choose between monitoring specific events or receiving general market-moving intelligence. Our AI automatically determines what’s critical based on real-time market data and the company’s current profile.

Receive Real-Time Intelligence

Once activated, all official filings are analyzed instantly. Insights are delivered directly to your email or as a push notification if you use the Portrak mobile app.

Also available as a mobile app for iOS & Android—search for "Portrak"

More Strategic Insights

MDT

Feb 17, 2026

Direct News

Historical Context

Quarter snapshot and EPS interpretation

What’s driving revenue — segments and geography

Capital allocation, innovation and strategic moves

Risk profile investors should weigh

Investor FAQ

More Strategic Insights

Medtronic Reports Strategic Growth Shift (Q3 FY26)

Medtronic Q3 Report: Growth, Guidance Upheld

Medtronic Issues $419M in New Shares — MDT

Medtronic Issues $419M in New Shares (MDT)